Episode
Chronic Myeloid Leukemia — An Interview with Prof Andreas Hochhaus
- Podcast
- Hematologic Oncology Update
- Published
- Sep 12, 2026
- Duration seconds
- 3589
- Processing state
not_requested
Actions
POST https://stenobird.com/v1/public/podcasts/hematologic-oncology-update-916423/episodes/chronic-myeloid-leukemia-an-interview-with-prof-andreas-hochhaus/transcription-requests
Idempotently request low-priority transcript generation for this episode.GET https://stenobird.com/podcast/hematologic-oncology-update-916423/chronic-myeloid-leukemia-an-interview-with-prof-andreas-hochhaus.md
Read the agent-friendly Markdown representation of this episode resource.
Summary
Featuring an interview with Prof Andreas Hochhaus, including the following topics: Biology of chronic myeloid leukemia (CML) and rationale for current therapeutic approaches; importance of cytogenetic testing (0:00) Mechanistic differences among first-generation tyrosine kinase inhibitors (TKIs), second-generation TKIs and asciminib (6:09) Potential mechanisms of adverse events documented with TKIs (10:23) Recent survey of patients with CML regarding goals of therapy and clinical implications; considerations for discontinuation of therapy (16:23) Comparative tolerability of asciminib and other agents used to manage CML; promoting adherence to treatment plans for patients (27:14) Comparative efficacy of asciminib and other agents used to treat CML (40:01) Potential areas for improvement in community oncology practice patterns; family planning in the context of CML treatment (43:53) Practical care strategies for CML patients; future developments (52:32) CME information and select publications